Abstract
Although adenosine plays a key role in multiple motor, affective, and cognitive processes, it has received less attention in the neuroscience field compared to other neurotransmitters (e.g., dopamine). In this review, we highlight the role of adenosine in behavior as well as its interaction with other neurotransmitters, such as dopamine. We also discuss brain disorders impacted by alterations to adenosine, and how targeting adenosine can ameliorate Parkinson’s disease motor symptoms. We also discuss the role of caffeine (as an adenosine antagonist) on cognition as well as a neuroprotective agent against Parkinson’s disease (PD).
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Change history
16 December 2019
The authors regret that the 3rd affiliation for author Ahmed A. Moustafa had been inadvertently omitted. The complete affiliations of the authors are presented above.
References
Cronstein B.N., Sitkovsky M. Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases. Nat Rev Rheumatol 2017;13(1):41–51.
Wall M, Dale N. Neuronal transporter and astrocytic ATP exocytosis underlie activity-dependent adenosine release in the hippocampus. J Physiol 2013;591:3853–71.
Sala-Newby GB, Skladanowski AC, Newby AC. The mechanism of adenosine formation in cells: cloning of cytosolic 50-nucleotidase-I. J Biol Chem 1999;274(25):17789–93.
Fredholm BB, Chen JF, Cunha RA, Svenningsson P, Vaugeois JM. Adenosine and brain function. Int Rev Neurobiol 2005;63:191–270.
Newby AC. The role of adenosine kinase in regulating adenosine concentration. Biochem J 1985;226:343–4.
Latini S, Pedata F. Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J Neurochem 2001;79:463–84.
Ribeiro J, Sebastiao A, De Mendonca A. Participation of adenosine receptors in neuroprotection. Drug News Perspect 2003;16(2):80–6.
Sebastiao AM, Ribeiro JA. Adenosine A2 receptor-mediated excitatory actions on the nervous system. Prog Neurobiol 1996;48:167–89.
Fredholm B. Adenosine receptors as drug targets. Exp Cell Res 2010;316(8):1284–8.
Muller CE, Jacobson KA. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta 2011;1808:1290–308.
Bruns RF, Lu GH, Pugsley TA. Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes. Mol Pharmacol 1986;29(4):331–46.
Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, Wasserman W. Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol 2000;362:364–74.
Rebola N, Pinheiro PC, Oliveira CR, Malva JO, Cunha RA. Subcellular localization of adenosine A(1) receptors in nerve terminals and synapses of the rat hippocampus. Brain Res 2003;987(1):49–58.
Cunha RA. Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors. Neurochem Int 2001;38:107–25.
Ferre S, Woods AS, Navarro G, Aymerich M, Lluis C, Franco R. Calcium-mediated modulation of the quaternary structure and function of adenosine A2A-dopamine D2 receptor heteromers. Curr Opin Pharmacol 2010;10(1):67–72.
Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol 2003;70:83–244.
Florio C, Prezioso A, Papaioannou A, Vertua R. Adenosine A1 receptors modulate anxiety in CD1 mice. Psychopharmacol 1998;136:311–9.
Prediger RD, Pamplona FA, Fernandes D, Takahash RN. Caffeine improves spatial learning deficits in an animal model of attention deficit hyperactivity disorder (ADHD)—The spontaneously hypertensive rat (SHR). Int J Neuropsychopharmacol 2005;8:583–94.
Gimenez-Llort L, Fernandez-Teruel A, Escorihuela RM, Fredholm BB, Tobena A, Pekny M. Mice lacking the adenosine A1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate. Eur J Neurosci 2002;16:547–50.
Alsene K, Deckert J, Sand P, de Wit H. Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 2003;28:1694–702.
Hamilton SP, Slager SL, De Leon AB, Heiman GA, Klein DF, Hodge SE. Evidence for genetic linkage between a polymorphism in the adenosine 2A receptor and panic disorder. Neuropsychopharmacology 2004;29:558–65.
ElYacoubi M, Ledent C, Parmentier M, Bertorelli R, Ongini E, Costentin J. Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. Br J Pharmacol 2001;134:68–77.
Kaster MP, Rosa AO, Rosso MM, Goulart EC, Santos AR, Rodrigues AL. Adenosine administration produces an antidepressant-like effect in mice: evidence for the involvement of A1 and A2A receptors. Neurosci Lett 2004;355:21–4.
Fredholm BB, I.Jzerman AP, Jacobson KA, Linden J, Muller CE. International union of basic and clinical pharmacology: LXXXI. Nomenclature and classification of adenosine receptors—an update. Pharmacol Rev 2011;63:1–34.
Zylka MJ. Pain-relieving prospects for adenosine receptors and ectonucleotidases. Trends Mol Med 2011;17:188–96.
Boison D. Adenosine kinase: exploitation for therapeutic gain. Pharmacol Rev 2013;65:906–43.
Abbracchio MP, Rainaldi G, Giammarioli AM, Ceruti S, Brambilla R, Cattabeni F. The A3 adenosine receptor mediates cell spreading, reorganization of actin cytoskeleton, and distribution of Bcl-XL: studies in human astroglioma cells. Biochem Biophys Res Commun 1997;241:297–304.
Ru F, Surdenikova L, Brozmanova M, Kollarik M. Adenosine-induced activation of esophageal nociceptors. Am J Physiol Gastrointest Liver Physiol 2011;300:G485–93.
Lopes LV, Rebola N, Pinheiro PC, Richardson PJ, Oliveira CR, Cunha RA. Adenosine A3 receptors are located in neurons of the rat hippocampus. Neuroreport 2003;14:1645–8.
Fishman P, Bar-Yehuda S, Liang BT, Jacobson KA. Pharmacological and therapeutic effects of A3adenosine receptor agonists. Drug Discov Today 2012;17:359–66.
Pitkänen A, Lukasiuk K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol 2011;10:173–86.
Biagini G, D’Antuono M, Benini R, de Guzman P, Longo D, Avoli M. Perirhinal cortex and temporal lobe epilepsy. Front Cell Neurosci 2013;7:31.
Barros-Barbosa A, Ferreirinha F, Oliveria A, Mendes M, Lobo M, Rangel R. Adenosine A2A receptor and ecto-5′-nucleotidase/CD73 are upregulated in hipocampal astrocytes of human patients with mesial temporal lobe epilepy (MTLE). Purinergic Signal 2016;12(4):719–34.
Matos M, Shen HY, Augusto E, Wang Y, Wei CJ, Wang YT, et al. Deletion of adenosine A2A receptors from astrocytes disrupts glutamate homeostasis leading to psychomotor and cognitive impairment: relevance to schizophrenia. Biol Psychiatry 2015;78(11):763–74.
Pereira GS, Rossato JI, Sarkis JJ, Cammarota M, Bonan CD, Izquierdo I. Activation of adenosine receptors in the posterior cingulate cortex impairs memory retrieval in the rat. Neurobiol Learning Mem 2005;83:217–23.
Maemoto T, Miho T, Takuma M, Noriko U, Hideaki M, Katsuya H. Pharmacological characterization of FR194921, a new potent, selective, orally active antagonist for central adenosine A1 receptors. J Pharmacol Sci 2004;96:42–52.
Pitsikas N, Borsini F. The adenosine A1 receptor antagonist BIIP 20 counteracts scopolamine-induced behavioral deficits in the passive avoidance task in the rat. Eur J Pharmacol 1997;328:19–22.
Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferre S. Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol 2007;83:277–92.
Yao L, McFarland K, Fan P, Jiang Z, Ueda T, Diamond I. Adenosine A2a blockade prevents synergy between mu-opiate and cannabinoidCB1 receptors and eliminates heroin-seeking behavior in addicted rats. Proc Natl Acad Sci 2006;103:7877–82.
Bastia E, Xu YH, Scibelli AC, Day YJ, Linden J, Chen JF. A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization. Neuropsychopharmacology 2005;30:891–900.
Shen HY, Coelho JE, Ohtsuka N, Canas PM, Day YJ, Huang QY. A critical role of the adenosine A2A receptor in extrastriatal neurons in modulating psychomotor activity as revealed by opposite phenotypes of striatum and forebrain A2A receptor knock-outs. J Neurosci 2008;28:2970–5.
Xiao D, Bastia E, Xu YH, Benn CL, Cha JH, Peterson TS. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J Neurosci 2006;26:13548–55.
Yao Lina, McFarland Krista, Fan Peidong, Jiang Zhan, Ueda Takashi, Diamond Ivan. Adenosine A2a blockade prevents synergy between m-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats. Proc Natl Acad Sci U S A 2006;103(20):7877–82.
Brown RM, Short JL. Adenosine A(2A) receptors and their role in drug addiction. J Pharm Pharmacol 2008;60(11):1409–30.
Martire A, Tebano MT, Chiodi V, Ferreira SG, Cunha RA, Kofalvi A. Pre-synaptic adenosine A2A receptors control cannabinoid CB1 receptormediated inhibition of striatal glutamatergic neurotransmission. J Neurochem 2011;116:273–80.
Basheer R, Strecker RE, Thakkar MM, McCarley RW. Adenosine and sleep-wake regulation. Prog Neurobiol 2004;73:379–96.
Basheer R, Porkka-Heiskanen T, Stenberg D, McCarley RW. Adenosine and behavioral state control: adenosine increases c-Fos protein and AP1 binding in basal forebrain of rats. Brain Res Mol Brain Res 1999;73:1–10.
Benington JH, Kodali SK, Heller HC. Stimulation of A1 adenosine receptors mimics the electroencephalographic effects of sleep deprivation. Brain Res 1995;692:79–85.
Ticho SR, Radulovacki M. Role of adenosine in sleep and temperature regulation in the preoptic area of rats. Pharmacol Biochem Behav 1991;40:33–40.
Thakkar MM, Winston S, McCarley RW. A1 receptor and adenosinergic homeostatic regulation of sleep-wakefulness: effects of antisense to the A1 receptor in the cholinergic basal forebrain. J Neurosci 2003;23:4278–87.
Huang ZL, Zhang Z, Qu WM. Roles of adenosine and its receptors in sleep-wake regulation. Int Rev Neurobiol 2014;119:349–71.
Satoh S, Matsumura H, Koike N, Tokunaga Y, Maeda T, Hayaishi O. Region-dependent difference in the sleep-promoting potency of an adenosine A2A receptor agonist. Euro J Neurosci 1995;11:1587–97.
Scammell TE, Gerashchenko DY, Mochizuki T, McCarthy MT, Estabrooke IV, Sears CA. An adenosine A2a agonist increases sleep and induces Fos in ventrolateral preoptic neurons. Neurosci 2001;107:653–63.
Hong ZY, Huang ZL, Qu WM, Eguchi N, Urade Y, Hayaishi O. An adenosine A receptor agonist induces sleep by increasing GABA release in the tuberomammillary nucleus to inhibit histaminergic systems in rats. J Neurochem 1995;92:1542–9.
Ruby CL, Adams CA, Knight EJ, Nam HW, Choi DS. An essential role for adenosine signaling in alcohol abuse. Curr Drug Abuse Rev 2010;3:163–74.
Pinna A, Bonaventura J, Farré D, Sánchez M, Simola N, Mallol J. L-DOPA disrupts adenosine A2A-cannabinoid CB1 dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies. Exp Neurol 2014;253:180–91.
Ferré S, Fredholm BB, Morelli M, Popoli P, Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basalganglia. Trends Neurosci 1997;20(10):482–7.
Ferré S, Popoli P, Rimondini R, Reggio R, Kehr J, Fuxe K. Adenosine A2A and group I metabotropic glutamate receptors synergistically modulate the binding characteristics of dopamine D2 receptors in the rat striatum. Neuropharmacology 1999;38(January (1)):129–40.
Childs E, Hohoff C, Deckert J, Xu K, Badner J, de Wit H. Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 2008;33:2791–800.
Fuxe K, Agnati LF, Jacobsen K, Hillion J, Canals M, Torvinen M, et al. Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson’s disease. Neurology 2003;61(11 Suppl. 6):S19–23.
Ballarin M, Reiriz J, Ambrosio S, Mahy N. Effect of locally infused 2-cholroadenosine, an A1 receptor agonist, on spontaneous and evoked dopamine release in rat neostriatum. Neurosci Lett 1995;185:29–32.
Quarta D, Borycz J, Solinas M, Patkar K, Hockemeyer J, Ciruela F, et al. Adenosine receptor-mediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmission and N-methyl-D-aspartate receptor stimulation. J Neurochem 2004;91(4):873–80.
Okada M, Mizuno K, Kaneko S. Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum. Neurosci Lett 1996;212(July 1):53–6.
Floran B, Barajas C, Floran L, Erlij D, Aceves J. Adenosine A1 receptors control dopamine D1-dependent [(3)H]GABA release in slices of substantia nigra pars reticulata and motor behavior in the rat. Neurosci 2002;115(3):743–51.
Jakowec M, Petzinger G. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced lesion model of Parkinson’s disease, with emphasis on mice and nonhuman primates. Comp Med 2004;54:497–13.
Campos-Romo A, Ojeda-Flores R, Moreno-Briseno P, Fernandez-Ruiz J. Quantitative evaluation of MPTP-treated nonhuman parkinsonian primates in the hallway task. J Neurosci Methods 2009;177:361–8.
Armentero M, Pinna A, Ferré S, Lanciego J, Müller C, Franco R. Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson’s disease. Pharmacol Ther 2011;132:280–99.
Ferraro L, Antonelli T, O’Connor W, Fuxe K, Soubrié P, Tanganelli S. The striatal neurotensin receptor modulates striatal and pallidal glutamate and GABA release: functional evidence for a pallidal glutamate-GABA interaction via the pallidal-subthalamic nucleus loop. Neurosci 1998;18:6977–89.
Koga K, Kurokawa M, Ochi M, Nakamura J, Kuwana Y. Adenosine A2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur J Pharmacol 2000;408(3):249–55.
Pinna A, Bonaventura J, Farré D, Sánchez M, Simola N, Mallol J, et al. L-DOPA disrupts adenosine A2A-cannabinoid CB1 dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies. Exp Neurol 2014;253:180–91.
Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M. Adenosine A2A receptor antagonist treatment of Parkinson’s disease. Neurology 2003;61:293–6.
Fathalla AM, Soliman AM, Ali HM, Moustafa AA. Adenosine A2A receptor blockade prevents rotenone-induced motor impairment in a rat model of parkinsonism. Front Behav Neurosci 2016;29:10–35.
Cabello N, Gandía J, Bertarelli D, Watanabe M, Lluís C, Franco R. Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells. J Neurochem 2009;109:1497–507.
Morin N, Di Paolo T. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson’s disease. Int Rev Neurobiol 2014;119:151–67.
Popoli P, Pèzzola A, Torvinen M, Reggio R, Pintor A, Scarchilli L. The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum:interactions with adenosine A(2a)receptors. Neuropsychopharmacology 2001;25:505–13.
Coccurello R, Breysse N, Amalric M. Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology 2004;29(8):1451–61.
Beggiato S, Tomasini MC, Borelli AC, Borroto-Escuela DO, Fuxe K, Antonelli T. Functional role of striatal A2A, D2, and mGlu5 receptor interactions in regulating striatopallidal GABA neuronal transmission. J Neurochem 2016;138(2):254–64.
Chen J, Eltzschig H, Fredholm BB. Adenosine receptors as drug targets — what are the challenges? Nat Rev Drug Discov 2013;12(4):265–86.
Fredholm BB, Battig K, Holmen J, Nehlig A, Avartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999;51(1):83–133.
Temple J. Caffeine use in children: what we know, what we have left to learn, and why we should worry. Neurosci Biobehav Rev 2009;33(6):793–806.
Frary CD, Johnson RK, Wang MQ. Food sources and intakes of caffeine in the diets of persons in the United States. J Am Diet Assoc 2005;105:110–3.
Gonzalez de Mejia E, Ramirez-Mares MV. Impact of caffeine and coffee on our health. Trends Endocrinol Metab 2014;25(10):489–92.
Yu L, Shen H, Coelho J, Araujo I, Huang QY, Day YJ. Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol 2008;63:338–46.
Glade MJ. Caffeine: not just a stimulant. Nutrition 2010;26(10):932–8.
Park CA, Kang CK, Son YD, Choi EJ, Kim SH, Oh ST. The effects of caffeine ingestion on cortical areas: functional imaging study. Magn Reson Imaging 2014;32(4):366–71.
Nehlig A. Is caffeine a cognitive enhancer? J Alzheimer’s Dis 2010;20:S85–94.
Bernstein GA, Carroll ME, Thurasc PD, Cosgrove KP, Roth ME. Caffeine dependence in teenagers. Drug Alcohol Depend 2002;66(l):l–6.
Borota D, Murray E, Keceli G, Chang A, Watabe JM, Ly M. Poststudy caffeine administration enhances memory consolidation in humans. Nat Neurosci 2014;17(2):201–3.
Smith AP. Caffeine, cognitive failures and health in a non-working community sample. Hum Psychopharmacol 2009;24(l):29–34.
Tucha O, Walitza S, Mecklinger L, Stasik D, Sontag TA, Lane KW. The effect of caffeine on handwriting movements in skilled writers. Hum Mov Sci 2006;25(4–5):523–35.
Arushanyan EB, Baida OA, Mastyagin SS, Popova AP, Shikina IB. Influence of caffeine on the subjective perception of time by healthy subjects in dependence on various factors. Fiziol Cheloveka 2003;29(4):433–6.
James JE, Rogers PJ. Effects of caffeine on performance and mood: withdrawal reversal is the most plausible explanation. Psychopharmacology (Berl) 2005;182:1–8.
Lara DR. Caffeine, mental health, and psychiatric disorders. J Alzheimers Dis 2010;20(l):S239–48.
Qj H, Li S. Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson’s disease. Geriatr Gerontol Int. 2014;2:430–9.
Moccia M, Erro R, Picillo M, Vitale C, Longo K, Amboni M, et al. Caffeine consumption and the 4-year progression of de novo Parkinson’s disease. Parkinsonism Relat Disord 2016;32:116–9.
Khadrawy YA, Salem AM, El-Shamy KA, Ahmed EK, Fadl NN, Hosny EN. Neuroprotective and therapeutic effect of caffeine on the rat model of Parkinson’s disease induced by rotenone. J Diet Suppl 2017;14(5):553–72.
Soliman A, Fathalla A, Moustafa A. Dose-dependent neuroprotective effect of caffeine on a rotenone-induced rat model of Parkinsonism: a histological study. Neurosci Lett 2016;623:63–70.
Hancock DB, Martin ER, Stajich JM, Jewett R, Stacy MA, Scott BL. Smoking, caffeine and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol 2007;64(4):576–80.
Chen Y, Parrish TB. Caffeine dose effect on activation-induced BOLD and CBF responses. Neuroimage 2009;46(3):577–83.
Gracia E, Moreno E, Cortés A, Lluís C, Mallol J, McCormick PJ. Homodimerization of adenosine Al receptors in brain cortex explains the biphasic effects of caffeine. Neuropharmacol 2013;71:56–69.
Tran A, Zhang CY, Cao C. The role of coffee in the therapy of Parkinson’s disease. J Alzheimers Dis Parkinsonism 2015;5:203.
Ritchie K, Carrière I, de Mendonça A, Dartigues F, Rouaud JF, Barberger-Gateau. The neuroprotective effects of caffeine: a prospective population study (the Three City Study). Neurology 2007;69(6):536–45.
Lim T, Fernandez H. Parkinson disease: current treatments and promising clinical trials. Neurobiology of Disease. 2nd ed. Oxford university press; 2016.
Christa E, Kenneth A. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta 2011;1808(5):1290–308.
Li M, Kang R, Shi J, Liu G, Zhang J. Anticonvulsant activity of B2, an adenosine analog, on chemical convulsant-induced seizures. PLoS One 2013;8(6):e67060.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Soliman, A.M., Fathalla, A.M. & Moustafa, A.A. Adenosine role in brain functions: Pathophysiological influence on Parkinson’s disease and other brain disorders. Pharmacol. Rep 70, 661–667 (2018). https://doi.org/10.1016/j.pharep.2018.02.003
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.pharep.2018.02.003